The challenge for gene therapy: Innate immune response to adenoviruses

Oncotarget

Volumn 2, Issue 3, 2011, Pages 113-121

  Thaci, Bart ^a   Ulasov, Ilya V ^a   Wainwright, Derek A ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adenovirus; Innate immune response; Interferon; Interleukin 1

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR;

ADENOVIRUS; CYTOKINE RESPONSE; INNATE IMMUNITY; INTERFERON INDUCTION; NONHUMAN; PARACRINE SIGNALING; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS MORPHOLOGY; VIRUS TRANSCRIPTION; ANIMAL; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; METHODOLOGY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

EID: 80052057856     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.231     Document Type: Review

References (75)

1. Ebner K, Rauch M, Preuner S, Lion T. Typing of human adenoviruses in specimens from immunosuppressed patients by PCR-fragment length analysis and real-time quantitative PCR. J Clin Microbiol 2006; 44: 2808-15.
2. Madisch I, Harste G, Pommer H, Heim A. Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy. J Virol 2005; 79: 15265-76.
3. Moro MR, Bonville CA, Suryadevara M, Cummings E, Faddoul D, Kobayaa H, Branigan PJ, Domachowske JB. Clinical features, adenovirus types, and local production of inflammatory mediators in adenovirus infections. Pediatr Infect Dis J 2009; 28: 376-80.
4. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-58.
5. Nemerow GR, Pache L, Reddy V, Stewart PL. Insights into adenovirus host cell interactions from structural studies. Virology 2009; 384: 380-8.
6. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004; 15: 1022-33.
7. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-3.
8. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-12.
9. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-19.
10. Trotman LC, Mosberger N, Fornerod M, Stidwill RP, Greber UF. Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat Cell Biol 2001; 3: 1092-100.
11. Suomalainen M, Nakano MY, Keller S, Boucke K, Stidwill RP, Greber UF. Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. J Cell Biol 1999; 144: 657-72.
12. Di Paolo NC, Miao EA, Iwakura Y, Murali-Krishna K, Aderem A, Flavell RA, Papayannopoulou T, Shayakhmetov DM. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity 2009; 31: 110-21.
13. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, Parks RJ, Tschopp J. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452: 103-7.
14. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors. J Immunol 2005; 174: 7310-9.
15. Gehart H, Kumpf S, Ittner A, Ricci R. MAPK signalling in cellular metabolism: stress or wellness? EMBO Rep; 11: 834-40.
16. Tamanini A, Nicolis E, Bonizzato A, Bezzerri V, Melotti P, Assael BM, Cabrini G. Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J Virol 2006; 80: 11241-54.
17. Verdino P, Witherden DA, Havran WL, Wilson IA. The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K. Science 2010; 329: 1210-4.
18. Philpott NJ, Nociari M, Elkon KB, Falck-Pedersen E. Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Natl Acad Sci U S A 2004; 101: 6200-5.
19. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003; 10: 935-40.
20. Uematsu S, Akira S. Toll-like receptors and Type I interferons. J Biol Chem 2007; 282: 15319-23.
21. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, Ohba Y, Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448: 501-5.
22. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-26.
23. Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci 1998; 856: 1-11.
24. Koizumi N, Yamaguchi T, Kawabata K, Sakurai F, Sasaki T, Watanabe Y, Hayakawa T, Mizuguchi H. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 2007; 178: 1767-73.
25. Xing Z, Zganiacz A, Wang J, Divangahi M, Nawaz F. IL-12-independent Th1-type immune responses to respiratory viral infection: requirement of IL-18 for IFN-gamma release in the lung but not for the differentiation of viralreactive Th1-type lymphocytes. J Immunol 2000; 164: 2575-84.
26. Alcorn MJ, Booth JL, Coggeshall KM, Metcalf JP. Adenovirus type 7 induces interleukin-8 production via activation of extracellular regulated kinase 1/2. J Virol 2001; 75: 6450-9.
27. Chintakuntlawar AV, Chodosh J. Chemokine CXCL1/ KC and its receptor CXCR2 are responsible for neutrophil chemotaxis in adenoviral keratitis. J Interferon Cytokine Res 2009; 29: 657-66.
28. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-76.
29. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580-90.
30. Tang Y, Reay DP, Salay MN, Mi MY, Clemens PR, Guttridge DC, Robbins PD, Huard J, Wang B. Inhibition of the IKK/NF-kappaB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther 2010.
31. Yuan X, Hu J, Belladonna ML, Black KL, Yu JS. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res 2006; 66: 2630-8.
32. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264: 1918-21.
33. Levraud JP, Boudinot P, Colin I, Benmansour A, Peyrieras N, Herbomel P, Lutfalla G. Identification of the zebrafish IFN receptor: implications for the origin of the vertebrate IFN system. J Immunol 2007; 178: 4385-94.
34. Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, Takeshita F, Ludwig H, Sutter G, Suzuki K, Hemmi H, Sato S, Yamamoto M, Uematsu S, Kawai T, Takeuchi O, Akira S. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006; 7: 40-8.
35. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7.
36. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
37. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptordependent and -independent pathways. J Virol 2007; 81: 3170-80.
38. Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, Hemmi H, Ohara O, Akira S, Kaisho T. IkappaB kinasealpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 2006; 440: 949-53.
39. Foy E, Li K, Sumpter R, Jr., Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005; 102: 2986-91.
40. Sen N, Sommer M, Che X, White K, Ruyechan WT, Arvin AM. Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J Virol 2010; 84: 9240-53.
41. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559-68.
42. Shi L, Ramaswamy M, Manzel LJ, Look DC. Inhibition of Jak1-dependent signal transduction in airway epithelial cells infected with adenovirus. Am J Respir Cell Mol Biol 2007; 37: 720-8.
43. Kitajewski J, Schneider RJ, Safer B, Munemitsu SM, Samuel CE, Thimmappaya B, Shenk T. Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase. Cell 1986; 45: 195-200.
44. Kochs G, Haller O. Interferon-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids. Proc Natl Acad Sci U S A 1999; 96: 2082-6.
45. Nociari M, Ocheretina O, Murphy M, Falck-Pedersen E. Adenovirus induction of IRF3 occurs through a binary trigger targeting Jun N-terminal kinase and TBK1 kinase cascades and type I interferon autocrine signaling. J Virol 2009; 83: 4081-91.
46. Zhu J, Huang X, Yang Y. A critical role for type I IFNdependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol Ther 2008; 16: 1300-7.
47. Schaack J. Induction and inhibition of innate inflammatory responses by adenovirus early region proteins. Viral Immunol 2005; 18: 79-88.
48. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91: 4407-11.
49. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 1994; 91: 6196-200.
50. Anderson KP, Fennie EH. Adenovirus early region 1A modulation of interferon antiviral activity. J Virol 1987; 61: 787-95.
51. Kalvakolanu DV, Bandyopadhyay SK, Harter ML, Sen GC. Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proc Natl Acad Sci U S A 1991; 88: 7459-63.
52. Weitzman MD, Ornelles DA. Inactivating intracellular antiviral responses during adenovirus infection. Oncogene 2005; 24: 7686-96.
53. Ilan Y, Droguett G, Chowdhury NR, Li Y, Sengupta K, Thummala NR, Davidson A, Chowdhury JR, Horwitz MS. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci U S A 1997; 94: 2587-92.
54. Carmody RJ, Maguschak K, Chen YH. A novel mechanism of nuclear factor-kappaB regulation by adenoviral protein 14.7K. Immunology 2006; 117: 188-95.
55. Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, Dimitrov T, Toth K, Wells CE, Doherty PC, Wold WS. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 1998; 392: 726-30.
56. Jackson MR, Nilsson T, Peterson PA. Retrieval of transmembrane proteins to the endoplasmic reticulum. J Cell Biol 1993; 121: 317-33.
57. Herrmann CH, Mathews MB. The adenovirus E1B 19-kilodalton protein stimulates gene expression by increasing DNA levels. Mol Cell Biol 1989; 9: 5412-23.
58. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-73.
59. Kuriyama S, Tominaga K, Kikukawa M, Tsujimoto T, Nakatani T, Tsujinoue H, Okuda H, Nagao S, Mitoro A, Yoshiji H, Fukui H. Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver. Gene Ther 1999; 6: 749-57.
60. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001; 8: 1347-53.
61. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478-91.
62. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J, Morita T, Francischetti IM, Monteiro RQ, Barouch DH, van Rooijen N, Napoli C, Havenga MJ, Nicklin SA, Baker AH. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.
63. Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA, van Rooijen N, Custers J, Goudsmit J, Barouch DH, McVey JH, Baker AH. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009; 114: 965-71.
64. Shashkova EV, May SM, Doronin K, Barry MA. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther 2009; 17: 2121-30.
65. Short JJ, Rivera AA, Wu H, Walter MR, Yamamoto M, Mathis JM, Curiel DT. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther 2010; 9: 2536-44.
66. Abe S, Okuda K, Ura T, Kondo A, Yoshida A, Yoshizaki S, Mizuguchi H, Klinman D, Shimada M. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J Gene Med 2009; 11: 570-9.
67. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008; 16: 16-29.
68. Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 2009; 20: 975-88.
69. Yao X, Yoshioka Y, Morishige T, Eto Y, Watanabe H, Okada Y, Mizuguchi H, Mukai Y, Okada N, Nakagawa S. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther 2009; 16: 1395-404.
70. Eto Y, Yoshioka Y, Ishida T, Yao X, Morishige T, Narimatsu S, Mizuguchi H, Mukai Y, Okada N, Kiwada H, Nakagawa S. Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol Pharm Bull 2010; 33: 1540-4.
71. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005; 11: 66-79.
72. Ferguson SD, Ahmed AU, Thaci B, Mercer RW, Lesniak MS. Crossing the boundaries: stem cells and gene therapy. Discov Med 2010; 9: 192-6.
73. Ahmed AU, Rolle CE, Tyler MA, Han Y, Sengupta S, Wainwright DA, Balyasnikova IV, Ulasov IV, Lesniak MS. Bone Marrow Mesenchymal Stem Cells Loaded With an Oncolytic Adenovirus Suppress the Anti-adenoviral Immune Response in the Cotton Rat Model. Mol Ther 2010; 18: 1846-1856.
74. Danks MK, Yoon KJ, Bush RA, Remack JS, Wierdl M, Tsurkan L, Kim SU, Garcia E, Metz MZ, Najbauer J, Potter PM, Aboody KS. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007; 67: 22-5.
75. Lanciotti J, Song A, Doukas J, Sosnowski B, Pierce G, Gregory R, Wadsworth S, O'Riordan C. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 2003; 8: 99-107.